Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Characteristics of healthy volunteers and patients with breast cancer

From: Circulating cell-free DNA-based epigenetic assay can detect early breast cancer

  Whole set (n = 278) Training set (n = 167) Validation set (n = 111)
Number of samples HVs 133 80 53
Patients with BC 145 87 58
Mean age (range) HVs 45.3 (22–70) 45.8 (26–70) 44.5 (22–66)
Patients with BC 59.5 (36–81) 59.8 (36–81) 59.1 (36–81)
Subtype Luminal 98 58 40
Triple-negative 25 14 11
HER2 10 6 4
Luminal HER2 8 6 2
not assessed (DCIS) 4 3 1
Stage 0 4 3 1
I 47 27 20
IIA 31 19 12
IIB 22 11 11
III 9 8 1
IV 32 19 13
Early BC (Stage0-I) Luminal 36 22 14
Triple-negative 8 3 5
HER2 2 2 0
Luminal HER2 1 0 1
not assessed (DCIS) 4 3 1
  1. HVs healthy volunteers, BC breast cancer, HER2 human epidermal growth factor receptor 2, DCIS ductal carcinoma in situ, Subtype immunohistochemically categorized subtype